Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
5.22
-0.06 (-1.14%)
At close: Jul 15, 2025, 4:00 PM
5.23
+0.01 (0.19%)
After-hours: Jul 15, 2025, 6:06 PM EDT
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 800 employees as of December 31, 2024. The number of employees increased by 300 or 60.00% compared to the previous year.
Employees
800
Change (1Y)
300
Growth (1Y)
60.00%
Revenue / Employee
$74,738
Profits / Employee
-$718,469
Market Cap
2.27B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RXRX News
- 7 days ago - What's Happening With RXRX Stock? - Forbes
- 5 weeks ago - Recursion to lay off 20% of workforce, narrows focus amid biotech downturn - Reuters
- 5 weeks ago - MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy - GlobeNewsWire
- 6 weeks ago - Recursion to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Recursion Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings - Seeking Alpha
- 2 months ago - Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden - GlobeNewsWire